Multimodal imaging measures to assess synaptic dysfunction in Alzheimer's disease

评估阿尔茨海默病突触功能障碍的多模态成像方法

基本信息

项目摘要

Alzheimer’s disease (AD) is the most common age-related neurodegenerative disorder, a relentless and fatal condition of progressive cognitive deficits. The urgency to find a cure for AD has never been stronger. Synaptic dysfunction and synapse loss are core deficits in AD pathophysiology. A better understanding of synaptic dysfunction in AD is imperative to develop effective therapeutic interventions. In this R21, we propose a multimodal imaging study combining structural and functional synaptic measures simultaneously to characterize synaptic failure in patients with AD. The multimodal composition of our study includes magnetoencephalography (MEG) to probe synapse physiology and positron emission tomography (PET) to probe synapse density, together with in-vivo quantification of amyloid (Aβ) and tau depositions. This proposal represents one of the very first to combine two sophisticated technologies to study synaptic failure in AD. On one hand, MEG provides quantitative spectral signatures of neural oscillations which represents the most direct, non-invasive, measures of neuronal and synaptic function in the human brain. Combining the fine spatiotemporal resolution of MEG spectral analyses with mathematical application of neural mass model (NMM) is a powerful technique to examine neuronal level details from non-invasive neuroimaging in human subjects. On the other hand, radioligands that bind to the synaptic vesicle glycoprotein 2A (SV2A) has recently become available to measure in-vivo synaptic density in the human brain. Here we propose to use a new second generation SV2A ligand, 18F-SynVesT-1, for the first time in AD research. Defining the relationships between synaptic density and synapse physiology and their specific relationships to Aβ and tau will broaden the current conceptualizations of AD pathophysiology and provide novel synaptic biomarkers for early interventional clinical trials. We will conduct a cross sectional pilot study of 45 participants: 25 Aβ-positive mild cognitive impairment (MCI) and mild-AD-dementia (CDR<1), and 20 age-matched cognitively unimpaired individuals (10 Aβ-negative and 10 Aβ-positive). All participants will undergo resting state MEG, structural MRI, 3-tracer PET imaging for SV2A (18F-18F-SynVesT-1), Aβ (florbetaben), and tau (flortaucipir), and complete cognitive and neuropsychological assessments. Our central hypothesis is that excitatory and inhibitory neuronal deficits will be correlated with reduced synaptic density (18F- SynVesT-1), and with Aβ and tau depositions (florbetaben and flortaucipir, respectively) in early clinical stage of AD. We will address two key aims. In Aim 1, we will determine the relationship between impaired synapse physiology (MEG and NMM) and synapse density (18F-SynVesT-1 retention) in AD. In Aim 2, we will Examine the associations between binding deficits of 18F-SynVesT-1 PET and AD pathophysiology and cognitive impairments in early clinical stage AD patients. This project will generate crucial data to define synaptic failure in patients with AD and preliminary data to design future studies linking clinical investigations in AD patients to mechanistic findings from basic science.
阿尔茨海默病(AD)是最常见的与年龄相关的神经退行性疾病,是一种无情而致命的疾病 进行性认知缺陷的状况。找到治疗阿尔茨海默病的方法的紧迫性前所未有地强烈。突触 功能障碍和突触丢失是AD病理生理学的核心缺陷。更好地理解突触 AD的功能障碍是开发有效的治疗干预措施的当务之急。在本R21中,我们建议 同时结合结构和功能突触测量的多模式成像研究 阿尔茨海默病患者的突触衰竭。我们研究的多模式组合包括脑磁图 (脑磁图)探测突触生理和正电子发射断层扫描(PET)探测突触密度, 以及体内淀粉样蛋白(Aβ)和tau沉积的量化。这项提议代表了非常重要的 首先,结合两项复杂的技术来研究AD的突触故障。一方面,梅格提供了 神经振荡的定量光谱特征,代表最直接、非侵入性的测量 在人脑中的神经元和突触功能。结合脑磁图的精细时空分辨率 光谱分析与神经质量模型(NMM)的数学应用是一种强有力的检测技术 来自人类受试者非侵入性神经成像的神经元水平细节。另一方面,放射性配体 结合突触囊泡糖蛋白2A(SV2A)最近已可用于测量体内突触 人脑中的密度。在这里,我们建议使用新的第二代SV2A配体,18F-SynVesT-1,用于 这是AD研究中的第一次。明确突触密度与突触生理的关系 它们与Aβ和tau的特殊关系将拓宽目前AD病理生理学的概念化和 为早期介入临床试验提供新的突触生物标志物。我们将进行一次横断面试验 对45名参与者的研究:25名β阳性的轻度认知障碍和轻度AD痴呆(CDR&lt;1),以及 20名年龄匹配的认知正常个体(10名Aβ阴性,10名Aβ阳性)。所有参与者将 接受静息状态脑磁图、结构磁共振、3-示踪剂正电子发射计算机断层扫描检查SV2a(18F-18F-SynVesT-1)、Aβ (氟倍他滨)和tau(氟他西平),并完成认知和神经心理评估。我们的中央 假设兴奋性和抑制性神经元缺陷将与突触密度降低相关(18F- SynVesT-1),并与Aβ和tau沉积(分别为氟倍他滨和氟他西平)在早期临床阶段 广告。我们将解决两个主要目标。在目标1中,我们将确定受损突触之间的关系 AD的生理学(MEG和NMM)和突触密度(18F-SynVesT-1保留)。在目标2中,我们将研究 18F-SynVesT-1PET结合缺陷与AD病理生理及认知功能的关系 临床早期阿尔茨海默病患者的损害。该项目将产生关键数据来定义突触故障 和初步数据来设计未来的研究,将AD患者的临床调查与 来自基础科学的机械论发现。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kamalini Gayathree Ranasinghe其他文献

Kamalini Gayathree Ranasinghe的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kamalini Gayathree Ranasinghe', 18)}}的其他基金

Neurophysiological Assessments of Network Dysfunction in Alzheimer's Disease
阿尔茨海默病网络功能障碍的神经生理学评估
  • 批准号:
    10377356
  • 财政年份:
    2019
  • 资助金额:
    $ 48.4万
  • 项目类别:
Neurophysiological Assessments of Network Dysfunction in Alzheimer's Disease
阿尔茨海默病网络功能障碍的神经生理学评估
  • 批准号:
    9916699
  • 财政年份:
    2019
  • 资助金额:
    $ 48.4万
  • 项目类别:
Neurophysiological Assessments of Network Dysfunction in Alzheimer's Disease
阿尔茨海默病网络功能障碍的神经生理学评估
  • 批准号:
    10623150
  • 财政年份:
    2019
  • 资助金额:
    $ 48.4万
  • 项目类别:
Spatiotemporal Patterns of Network Dysfunction in Alzheimer's Disease
阿尔茨海默病网络功能障碍的时空模式
  • 批准号:
    9051982
  • 财政年份:
    2016
  • 资助金额:
    $ 48.4万
  • 项目类别:
Spatiotemporal Patterns of Network Dysfunction in Alzheimer's Disease
阿尔茨海默病网络功能障碍的时空模式
  • 批准号:
    9231998
  • 财政年份:
    2016
  • 资助金额:
    $ 48.4万
  • 项目类别:

相似海外基金

Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
  • 批准号:
    495182
  • 财政年份:
    2023
  • 资助金额:
    $ 48.4万
  • 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
  • 批准号:
    2601817
  • 财政年份:
    2021
  • 资助金额:
    $ 48.4万
  • 项目类别:
    Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
  • 批准号:
    2029039
  • 财政年份:
    2020
  • 资助金额:
    $ 48.4万
  • 项目类别:
    Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
  • 批准号:
    9888417
  • 财政年份:
    2019
  • 资助金额:
    $ 48.4万
  • 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
  • 批准号:
    17K11318
  • 财政年份:
    2017
  • 资助金额:
    $ 48.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9320090
  • 财政年份:
    2017
  • 资助金额:
    $ 48.4万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    10166936
  • 财政年份:
    2017
  • 资助金额:
    $ 48.4万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9761593
  • 财政年份:
    2017
  • 资助金额:
    $ 48.4万
  • 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
  • 批准号:
    BB/M50306X/1
  • 财政年份:
    2014
  • 资助金额:
    $ 48.4万
  • 项目类别:
    Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
  • 批准号:
    288272
  • 财政年份:
    2013
  • 资助金额:
    $ 48.4万
  • 项目类别:
    Miscellaneous Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了